Details

Autor(en) / Beteiligte

• Macchia, G
• Lazzari, R
• Colombo, N
• Laliscia, C
• Capelli, G
• D’Agostino, GR
• Deodato, F
• Trippa, F
• Ippolito, E
• Ronchi, S
• Pajar, F
• Scorsetti, M
• Cilla, S
• Ingargiola, R
• Huscher, A
• Cerrotta, AM
• Andrei, F
• Vicenzi, L
• Russo, D
• Borghesi, S
• Perrucci, E
• Pignata, S
• Aristei, C
• Morganti, AG
• Scambia, G
• Valentini, V
• Jereczek-Fossa, BA
• Ferrandina, G

Titel

19 A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 study)

Ist Teil von

• International journal of gynecological cancer, 2019-09, Vol.29 (Suppl 3), p.A12-A12

Ort / Verlag

Oxford: by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology

Erscheinungsjahr

2019

Beschreibungen/Notizen

• ObjectivesThe aim of this retrospective, multicenter study (MITO RT-01) was to define activity and safety of Stereotactic Body Radiotherapy (SBRT) in a very large, real life dataset of metastatic/persistent/recurrent ovarian cancer (MPR-OC) patients. Clinical and SBRT parameters have been analyzed in order to identify predictors of outcome.MethodsThe endpoints of the study were the rate of complete response (CR) to SBRT, and the 24-month actuarial local control (LC) rate on “per lesion” basis. The secondary end-points were acute and late toxicities, and the 24-month actuarial late toxicity free survival. Toxicity was evaluated by RTOG/EORTC and CTC-AE scales, according to center policy. Logistic and Cox regression were used for the uni- and multivariate analysis of factors predicting clinical CR and actuarial outcomes.ResultsCR, PR and SD were observed in 291 (65.2%), 106 (23.8%), and 33 (7.4%) lesions. Patient age <60 years, PTV <18 cm3, lymph node disease, and BEDα/β10 >70 Gy were associated with higher chance of CR in the multivariate analysis. With a median follow-up of 22 months (range: 3–120), the 24-month actuarial LC rate was 81.9%. Achievement of CR and total dose >25 Gy were associated with better LC rate in the multivariate analysis. Mild toxicity was experienced in 54 (20.7%) patients. The 24- month late toxicity free survival rate was 95.1%.ConclusionsThis study confirms the activity and safety of SBRT in MPR-OC patients and identifies clinical and treatment parameters able to predict CR and LC rate.